• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardlytics First Quarter 2026 Financial Results Driven By Strong Operational Performance

    5/7/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email
    • Company delivers strong first quarter results:
      • Revenues from continuing operations $34.3 million; additional $4.2 million from Bridg discontinued operations
      • Billings from continuing operations of $58.1 million; additional $4.2 million from Bridg discontinued operations
      • Adjusted Contribution from continuing operations of $19.7 million; additional $3.6 million from Bridg discontinued operations
    • Successfully completed the divestiture of Bridg on March 24, 2026
    • Subsequently liquidated PAR shares, further bolstering the balance sheet

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the first quarter ended March 31, 2026.

    "The first quarter of 2026 marks a definitive shift from stabilization to execution. By exceeding the midpoint of our guidance range across all key metrics, we have demonstrated that our leaner, more disciplined operating model is delivering real results," said Amit Gupta, CEO of Cardlytics. "While we navigated the anticipated shift in our banking mix, our ability to drive high-intent commerce for our advertisers remains our core competitive advantage. We have a clear and focused path to drive long-term value for our shareholders."

    "We continue to execute against our game plan for achieving sequential growth and self sustainability throughout 2026," said David Evans, CFO of Cardlytics.

    First Quarter 2026 Financial Results

    • Revenue was $34.3 million, a decrease of 39% year-over-year compared to $56.4 million in the first quarter of 2025.
    • Billings, a non-GAAP metric, was $58.1 million, a decrease of 37% year-over-year compared to $92.1 million in the first quarter of 2025.
    • Adjusted Contribution, a non-GAAP metric, was $19.7 million, a decrease of 28% year-over-year compared to $27.3 million in the first quarter of 2025.
    • Net Loss was $(4.5) million, or $(0.08) per diluted share, based on 54.9 million fully diluted weighted-average common shares, compared to a Net Loss of $(13.3) million, or $(0.26) per diluted share, based on 51.9 million fully diluted weighted-average common shares in the first quarter of 2025.
    • Adjusted EBITDA, a non-GAAP metric, was $0.2 million compared to $(4.1) million in the first quarter of 2025.
    • Adjusted Net Loss was $(6.2) million, or $(0.11) per diluted share, based on 54.9 million fully diluted weighted-average common shares, compared to Adjusted Net Loss of $(10.3) million, or $(0.20) per diluted share, based on 51.9 million fully diluted weighted-average common shares in the first quarter of 2025.
    • Net cash used by operating activities was $(5.6) million, compared to $(6.7) million in the first quarter of 2025.
    • Free Cash Flow, a non-GAAP metric, was $(7.9) million, compared to $(10.8) million in the first quarter of 2025.

    Key Metrics

    • Cardlytics monthly qualified users ("MQUs") were 197.0 million, a decrease of 8% year-over-year, compared to 214.9 million in the first quarter of 2025.
    • Cardlytics adjusted contribution per user ("ACPU") was $0.10 compared to $0.13 in the first quarter of 2025.

    Definitions of MQUs and ACPU are included below under the caption "Other Performance Metrics."

    CARDLYTICS, INC.

    SUMMARY OF GAAP AND NON-GAAP RESULTS (UNAUDITED)

    (Dollars in thousands)

     

     

    Three Months Ended

    March 31,

     

     

     

    2026

     

    2025

     

    Change %

    Billings(1)(2)

    $

    58,146

     

     

    $

    92,115

     

     

    (37

    )%

    Consumer Incentives(2)

     

    23,827

     

     

     

    35,680

     

     

    (33

    )%

    Revenue(2)

     

    34,319

     

     

     

    56,435

     

     

    (39

    )%

    Partner Share and other third-party costs(2)

     

    14,597

     

     

     

    29,104

     

     

    (50

    )%

    Adjusted Contribution(1)(2)

     

    19,722

     

     

     

    27,331

     

     

    (28

    )%

    Delivery costs(2)

     

    2,581

     

     

     

    5,786

     

     

    (55

    )%

    Gross Profit(2)

    $

    17,141

     

     

    $

    21,545

     

     

    (20

    )%

    Net Loss(2)

    $

    (4,480

    )

     

    $

    (13,282

    )

     

    66

    %

    Adjusted EBITDA(1)(2)

    $

    230

     

     

    $

    (4,119

    )

     

    106

    %

     

     

     

     

     

     

    Adjusted Contribution

     

     

     

     

     

    % of Billings

     

    33.9

    %

     

     

    29.7

    %

     

     

    % of Revenue

     

    57.5

    %

     

     

    48.4

    %

     

     

    Adjusted EBITDA

     

     

     

     

     

    % of Billings

     

    0.4

    %

     

     

    (4.5

    )%

     

     

    % of Revenue

     

    0.7

    %

     

     

    (7.3

    )%

     

     

    (1)

    Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA." In addition, reconciliations of Bridg discontinued operations Billings and Adjusted Contribution to the most comparable GAAP measures are presented below under the heading "Reconciliation of Bridg Revenue and Gross Profit to Billings, Adjusted Contribution and Income (Loss) from Discontinued Operations".

    (2)

    Revenues, Consumer Incentives, Billings, Gross Profit, Adjusted Contribution, Net Loss and Adjusted EBITDA reflect the effects of disposed businesses through the respective disposal dates. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

    Second Quarter 2026 Financial Expectations

    Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates):

     

    Q2 2026 Guidance

     

    YoY Change

    Billings(1)

    $61.0 - $67.0

     

    (38%) - (32%)

    Revenue

    $35.0 - $40.0

     

    (40%) - (31%)

    Adjusted Contribution(2)

    $20.0 - $23.0

     

    (36%) - (27%)

    Adjusted EBITDA(2)

    ($2.7) - $1.3

     

    ($5.7) - ($1.7)

    (1)

    A reconciliation of Billings to GAAP Revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."

    (2)

    A reconciliation of Adjusted Contribution to GAAP Gross Profit and a reconciliation of Adjusted EBITDA to Net Loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

    Earnings Teleconference Information

    Cardlytics will discuss its first quarter 2026 financial results during a live audio webcast today, May 7, 2026, at 5:00 PM ET / 2:00 PM PT. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics' website.

    About Cardlytics

    Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that makes commerce smarter and more rewarding for everyone. We offer a range of solutions to help advertisers and publishers grow and strengthen customer loyalty. With visibility into approximately half of all card-based transactions in the U.S. and a quarter in the U.K., Cardlytics enables advertisers to engage consumers at scale and drive incremental sales through our industry-leading card-linked offer network. Publisher partners can enhance their platforms with relevant and personalized offers that improve the shopping experience for their customers. Learn more at www.cardlytics.com or follow us on LinkedIn.

    Cautionary Language Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to driving long-term value for shareholders and our financial guidance for the second quarter of 2026. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

    Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions, including, but not limited to, inflationary pressure or the imposition of tariffs and other trade protection measures, in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association ("Chase"), Wells Fargo Bank, National Association ("Wells Fargo") and a limited number of other financial institution ("FI") partners; risks related to our ability to maintain relationships with Chase and Wells Fargo; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors; our ability to generate sufficient revenue to offset contractual commitments to FI partners; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; risks related to our competitive market, including our ability to compete successfully with our current or future competitors; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; and other risks detailed in the "Risk Factors" section of our Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

    The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Divestitures and Presentation

    On March 24, 2026 (the "Closing Date"), we completed the Bridg Sale. Pursuant to the Purchase Agreement, on the Closing Date, PAR delivered to us 1,810,222 shares of PAR's common stock as consideration for the Bridg Sale.

    The results of Bridg business are presented as discontinued operations in the accompanying Condensed Consolidated Statements of Operations for all periods presented. The assets and liabilities of Bridg business have been reflected as assets and liabilities of discontinued operations in the accompanying Condensed Consolidated Balance Sheets for all prior periods presented. The Company ceased depreciating and amortizing its long-lived assets for the Bridg business which primarily included acquired intangibles assets, capitalized software, and right-of-use assets as of the held for sale date, during the three months ended March 31, 2026. Our consolidated statements of cash flows includes cash flows from discontinued operations for all periods presented.

    Non-GAAP Measures and Other Performance Metrics

    To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of financial performance in this press release: Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss, Adjusted Net Loss per share and Free Cash Flow, as well as certain other performance metrics, such as MQUs and ACPU.

    A "non-GAAP financial measure" refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.

    We have presented Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss and Adjusted Net Loss per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform Billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP Revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform Billings is the same as Bridg platform GAAP Revenue. Adjusted Contribution measures the degree by which Revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted Contribution demonstrates how incremental Revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administrative and other investments. Adjusted Contribution is calculated by taking our total Revenue less our Partner Share and other third-party costs. Adjusted Contribution does not take into account all costs associated with generating Revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. Management views Adjusted Contribution as the most relevant metric to measure the financial performance as it reflects the dollars we keep after all of our partners are paid. Adjusted EBITDA represents our Net Loss before interest expense, net; depreciation and amortization; stock-based compensation expense continuing operations; foreign currency loss (gain); loss on investment; change in contingent consideration and Income (loss) from discontinued operations and, in applicable periods, certain other income and expense items, such as impairment of goodwill and intangible assets; income tax benefit; gain on debt extinguishment; reduction in force and deferred implementation costs. Adjusted Net Loss as our Net Loss before stock-based compensation expense continuing operations; foreign currency loss (gain); loss on investment; gain on divestiture; change in contingent consideration; and, in applicable periods, certain other income and expense items, such as impairment of goodwill, gain on debt extinguishment and intangible assets, reduction in force and income tax benefit. We define Adjusted Net Loss per share as Adjusted Net Loss divided by our weighted-average common shares outstanding, diluted. We define Free Cash Flow as net cash used in operating activities, plus acquisition of property and equipment and capitalized software development costs and, in applicable periods, acquisition of patents. We believe free cash flow is useful to measure the funds generated in a given period that are available for distribution or to sustain the business. We believe this supplemental information enhances stockholders' ability to evaluate our performance.

    We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance.

    We define MQUs as targetable customers that have made a transaction using their account with an FI Partner or non-FI Partner in a given month, excluding pilot supply during the ramp up period, and whose transaction data was shared with Cardlytics. We then calculate a monthly average of these MQUs for the periods presented. We believe that the number of MQUs is an indicator of the Cardlytics platform's ability to drive engagement and is reflective of the consumer base and insights that we offer to marketers. We define ACPU as the Cardlytics platform Adjusted Contribution generated in the applicable period, divided by Cardlytics average MQUs in the applicable period. We believe that Adjusted Contribution is the most relevant metric as it reflects the value Cardlytics keeps after subtracting out rewards, Partner Share and other third-party costs. We believe that ACPU measures the Cardlytics platform's efficiency in converting marketer budgets into the value generated by customer engagement.

    CARDLYTICS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

    (Amounts in thousands, except par value amounts)

     

     

    March 31,

    2026

     

    December 31,

    2025

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    35,673

     

     

    $

    48,719

     

    Marketable securities

     

    24,130

     

     

     

    —

     

    Accounts receivable and contract assets, net

     

    63,076

     

     

     

    82,458

     

    Other receivables

     

    2,674

     

     

     

    2,474

     

    Prepaid expenses and other assets

     

    2,966

     

     

     

    3,213

     

    Current assets of discontinued operations

     

    —

     

     

     

    415

     

    Total current assets

     

    128,519

     

     

     

    137,279

     

    Long-term assets:

     

     

     

    Property and equipment, net

     

    1,743

     

     

     

    1,931

     

    Right-of-use assets under operating leases, net

     

    4,403

     

     

     

    4,723

     

    Goodwill

     

    110,305

     

     

     

    110,305

     

    Capitalized software development costs, net

     

    17,779

     

     

     

    19,005

     

    Other long-term assets, net

     

    1,160

     

     

     

    1,235

     

    Noncurrent assets of discontinued operations

     

    —

     

     

     

    11,163

     

    Total assets

    $

    263,909

     

     

    $

    285,641

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    2,600

     

     

    $

    2,655

     

    Accrued liabilities:

     

     

     

    Accrued compensation

     

    4,572

     

     

     

    6,038

     

    Accrued expenses

     

    9,918

     

     

     

    7,125

     

    Partner Share liability

     

    17,470

     

     

     

    24,792

     

    Consumer Incentive liability

     

    20,586

     

     

     

    32,144

     

    Deferred revenue and other liabilities

     

    2,738

     

     

     

    2,541

     

    Current operating lease liabilities

     

    1,467

     

     

     

    1,438

     

    Current liabilities of discontinued operations

     

    —

     

     

     

    1,657

     

    Total current liabilities

    $

    59,351

     

     

    $

    78,390

     

    Long-term liabilities:

     

     

     

    Convertible senior notes, net

    $

    169,131

     

     

    $

    168,850

     

    Lines of credit

     

    35,070

     

     

     

    40,070

     

    Long-term operating lease liabilities

     

    4,360

     

     

     

    4,748

     

    Long-term liabilities of discontinued operations

     

    —

     

     

     

    91

     

    Total liabilities

    $

    267,912

     

     

    $

    292,149

     

    Stockholders' deficit:

     

     

     

    Common stock, $0.0001 par value—100,000 shares authorized and 55,071 and 54,514 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.

    $

    10

     

     

    $

    10

     

    Additional paid-in capital

     

    1,405,063

     

     

     

    1,399,542

     

    Accumulated other comprehensive loss

     

    (532

    )

     

     

    (1,996

    )

    Accumulated deficit

     

    (1,408,544

    )

     

     

    (1,404,064

    )

    Total stockholders' deficit

     

    (4,003

    )

     

     

    (6,508

    )

    Total liabilities and stockholders' deficit

    $

    263,909

     

     

    $

    285,641

     

    CARDLYTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

    (Amounts in thousands, except per share amounts)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Revenue

    $

    34,319

     

     

    $

    56,435

     

    Costs and expenses:

     

     

     

    Partner Share and other third-party costs

     

    14,597

     

     

     

    29,104

     

    Delivery costs

     

    2,581

     

     

     

    5,786

     

    Sales and marketing expense

     

    6,761

     

     

     

    10,382

     

    Research and development expense

     

    6,430

     

     

     

    10,278

     

    General and administrative expense

     

    8,281

     

     

     

    12,943

     

    Change in contingent consideration

     

    —

     

     

     

    60

     

    Gain on divestiture

     

    —

     

     

     

    (5,350

    )

    Depreciation and amortization expense

     

    3,943

     

     

     

    4,347

     

    Total costs and expenses

     

    42,593

     

     

     

    67,550

     

    Operating loss

     

    (8,274

    )

     

     

    (11,115

    )

    Other income (expense):

     

     

     

    Interest expense, net

     

    (2,533

    )

     

     

    (1,830

    )

    Loss on investment

     

    (1,285

    )

     

     

    —

     

    Foreign currency (loss) gain

     

    (1,706

    )

     

     

    2,627

     

    Total other income (expense)

     

    (5,524

    )

     

     

    797

     

    Loss before income taxes from continuing operations

     

    (13,798

    )

     

     

    (10,318

    )

    Income tax benefit

     

    —

     

     

     

    —

     

    Loss from continuing operations

     

    (13,798

    )

     

     

    (10,318

    )

    Income (loss) from discontinued operations

     

    9,318

     

     

     

    (2,964

    )

    Net loss

    $

    (4,480

    )

     

    $

    (13,282

    )

    Net (loss) income per share, basic and diluted:

     

     

     

    Continuing operations

    $

    (0.25

    )

     

    $

    (0.20

    )

    Discontinued operations

    $

    0.17

     

     

    $

    (0.06

    )

    Weighted-average common shares outstanding, basic and diluted

     

    54,896

     

     

     

    51,863

     

    CARDLYTICS, INC.

    STOCK-BASED COMPENSATION EXPENSE (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Delivery costs

    $

    268

     

    $

    473

    Sales and marketing expense

     

    708

     

     

    1,605

    Research and development expense

     

    1,993

     

     

    2,799

    General and administrative expense

     

    1,592

     

     

    3,062

    Discontinued operations

     

    267

     

     

    755

    Total stock-based compensation expense

    $

    4,828

     

    $

    8,694

    CARDLYTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Operating activities

     

     

     

    Net loss

    $

    (4,480

    )

     

    $

    (13,282

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Credit loss expense

     

    335

     

     

     

    643

     

    Depreciation and amortization

     

    4,418

     

     

     

    6,291

     

    Amortization of financing costs charged to interest expense

     

    330

     

     

     

    405

     

    Amortization of right-of-use assets

     

    322

     

     

     

    632

     

    Gain on divestiture

     

    (14,543

    )

     

     

    (5,350

    )

    Stock-based compensation expense

     

    4,828

     

     

     

    8,694

     

    Change in contingent consideration

     

    —

     

     

     

    60

     

    Loss on investments

     

    1,285

     

     

     

    —

     

    Other non-cash expense (income), net

     

    1,764

     

     

     

    (2,620

    )

    Change in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    18,316

     

     

     

    7,536

     

    Prepaid expenses and other assets

     

    154

     

     

     

    (56

    )

    Accounts payable

     

    (167

    )

     

     

    551

     

    Other accrued expenses

     

    586

     

     

     

    1,895

     

    Partner Share liability

     

    (7,238

    )

     

     

    (3,860

    )

    Consumer Incentive liability

     

    (11,552

    )

     

     

    (8,245

    )

    Net cash used in operating activities

     

    (5,642

    )

     

     

    (6,706

    )

    Investing activities

     

     

     

    Acquisition of property and equipment

     

    (28

    )

     

     

    (119

    )

    Capitalized software development costs

     

    (2,276

    )

     

     

    (3,984

    )

    Proceeds from divestiture, net of cash divested

     

    —

     

     

     

    200

     

    Net cash used in investing activities

     

    (2,304

    )

     

     

    (3,903

    )

    Financing activities

     

     

     

    Proceeds from issuance of debt

     

    5,000

     

     

     

    —

     

    Settlement of contingent consideration

     

    —

     

     

     

    (3,000

    )

    Principal payment of debt

     

    (10,000

    )

     

     

    —

     

    Debt issuance costs

     

    (22

    )

     

     

    (34

    )

    Net cash used in financing activities

     

    (5,022

    )

     

     

    (3,034

    )

    Effect of exchange rates on cash and cash equivalents

     

    (78

    )

     

     

    95

     

    Net decrease in cash and cash equivalents

     

    (13,046

    )

     

     

    (13,548

    )

    Cash and cash equivalents — Beginning of period

     

    48,719

     

     

     

    65,594

     

    Cash and cash equivalents — End of period

    $

    35,673

     

     

    $

    52,046

     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP REVENUE TO BILLINGS (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Revenue(1)

    $

    34,319

     

    $

    56,435

    Plus:

     

     

     

    Consumer Incentives

     

    23,827

     

     

    35,680

    Billings(1)

    $

    58,146

     

    $

    92,115

    (1)

    Revenue and Billings reflect the effects of disposed businesses through the respective disposal dates. Refer to Note 3—Discontinued Operations to our consolidated financial statements in our Quarterly Report on Form 10-Q for the three months ended March 31, 2026 for additional information regarding the divestiture of the Bridg business.

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Revenue(1)

    $

    34,319

     

    $

    56,435

    Minus:

     

     

     

    Partner Share and other third-party costs(1)

     

    14,597

     

     

    29,104

    Delivery costs(1)(2)

     

    2,581

     

     

    5,786

    Gross Profit(1)

     

    17,141

     

     

    21,545

    Plus:

     

     

     

    Delivery costs(1)(2)

     

    2,581

     

     

    5,786

    Adjusted Contribution(1)

    $

    19,722

     

    $

    27,331

    (1)

    Revenue, Partner Share and other third-party costs, Delivery costs, Gross Profit and Adjusted Contribution reflect the effects of disposed businesses through the respective disposal dates. Refer to Note 3—Discontinued Operations to our consolidated financial statements in our Quarterly Report on Form 10-Q for the three months ended March 31, 2026 for additional information regarding the divestiture of the Bridg business.

    (2)

    Stock-based compensation expense recognized in consolidated delivery costs totaled $0.3 million and $0.5 million during the three months ended March 31, 2026 and 2025, respectively.

    RECONCILIATION OF BRIDG REVENUE AND, GROSS PROFIT TO BILLINGS, ADJUSTED CONTRIBUTION AND INCOME (LOSS) FROM DISCONTINUED OPERATIONS (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Revenue(1)

    $

    4,175

     

     

    $

    5,463

     

    Minus:

     

     

     

    Partner Share and other third-party costs

     

    589

     

     

     

    346

     

    Delivery costs

     

    1,364

     

     

     

    1,502

     

    Gross Profit(1)

     

    2,222

     

     

     

    3,615

     

    Plus:

     

     

     

    Delivery costs

     

    1,364

     

     

     

    1,502

     

    Adjusted Contribution(1)

     

    3,586

     

     

     

    5,117

     

    Minus:

     

     

     

    Delivery costs

     

    1,364

     

     

     

    1,502

     

    Sales and marketing expense

     

    929

     

     

     

    2,372

     

    Research and development

     

    552

     

     

     

    1,428

     

    General and administrative

     

    3,460

     

     

     

    835

     

    Divestiture costs

     

    2,031

     

     

     

    —

     

    Gain on divestiture

     

    (14,543

    )

     

     

    —

     

    Depreciation and amortization expense

     

    475

     

     

     

    1,944

     

    Income (loss) from discontinued operations

    $

    9,318

     

     

    $

    (2,964

    )

    (1)

    Bridg revenue equals billings.

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Net Loss

    $

    (4,480

    )

     

    $

    (13,282

    )

    Plus:

     

     

     

    Interest expense, net

     

    2,533

     

     

     

    1,830

     

    Depreciation and amortization

     

    3,943

     

     

     

    4,347

     

    Stock-based compensation expense continuing operations

     

    4,561

     

     

     

    7,939

     

    Foreign currency loss (gain)

     

    1,706

     

     

     

    (2,627

    )

    Loss on investment

     

    1,285

     

     

     

    —

     

    Gain on divestiture

     

    —

     

     

     

    (5,350

    )

    Change in contingent consideration

     

    —

     

     

     

    60

     

    (Income) loss from discontinued operations

     

    (9,318

    )

     

     

    2,964

     

    Adjusted EBITDA

    $

    230

     

     

    $

    (4,119

    )

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED NET LOSS

    AND ADJUSTED NET LOSS PER SHARE (UNAUDITED)

    (Amounts in thousands, except per share amounts)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Net Loss

    $

    (4,480

    )

     

    $

    (13,282

    )

    Plus:

     

     

     

    Stock-based compensation expense continuing operations

     

    4,561

     

     

     

    7,939

     

    Foreign currency loss (gain)

     

    1,706

     

     

     

    (2,627

    )

    Loss on investment

     

    1,285

     

     

     

    —

     

    Gain on divestiture

     

    —

     

     

     

    (5,350

    )

    Change in contingent consideration

     

    —

     

     

     

    60

     

    (Income) loss from discontinued operations, net of tax

     

    (9,318

    )

     

     

    2,964

     

    Adjusted Net Loss

    $

    (6,246

    )

     

    $

    (10,296

    )

    Weighted-average number of shares of common stock used in computing Adjusted Net Income (Loss) per share:

     

     

     

    Weighted-average common shares outstanding, diluted

     

    54,896

     

     

     

    51,863

     

    Adjusted Net Income (Loss) per share, diluted

    $

    (0.11

    )

     

    $

    (0.20

    )

    CARDLYTICS, INC.

    RECONCILIATION OF NET CASH USED IN OPERATING ACTIVITIES TO FREE CASH FLOW (UNAUDITED)

    (Amounts in thousands)

     

     

    Three Months Ended

    March 31,

     

    2026

     

    2025

    Net cash used in operating activities

    $

    (5,642

    )

     

    $

    (6,706

    )

    Plus:

     

     

     

    Acquisition of property and equipment

     

    (28

    )

     

     

    (119

    )

    Capitalized software development costs

     

    (2,276

    )

     

     

    (3,984

    )

    Free Cash Flow

    $

    (7,946

    )

     

    $

    (10,809

    )

    CARDLYTICS, INC.

    RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS (UNAUDITED)

    (Amounts in thousands)

     

     

    Q2 2026

    Revenue

    $35.0 - $40.0

    Plus:

     

    Consumer Incentives

    $26.0 - 27.0

    Billings

    $61.0 - $67.0

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260507732145/en/

    Public Relations:

    pr@cardlytics.com

    Investor Relations:

    ir@cardlytics.com

    Get the next $CDLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardlytics First Quarter 2026 Financial Results Driven By Strong Operational Performance

    Company delivers strong first quarter results: Revenues from continuing operations $34.3 million; additional $4.2 million from Bridg discontinued operations Billings from continuing operations of $58.1 million; additional $4.2 million from Bridg discontinued operations Adjusted Contribution from continuing operations of $19.7 million; additional $3.6 million from Bridg discontinued operations Successfully completed the divestiture of Bridg on March 24, 2026 Subsequently liquidated PAR shares, further bolstering the balance sheet Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the first quarter ended March 31, 2026. "The

    5/7/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that on April 29, 2026, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 272,000 restricted stock units of Cardlytics to six newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). For all of the grant recipients, 50% of the restricted stock units shall vest on the first anniversary of the grant date, and the remaining 50% shall vest quarterly over the subsequent 12 months, subject to the employees' conti

    5/1/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    CORRECTING and REPLACING Cardlytics Announces Timing of Its First Quarter 2026 Earnings Release

    Link to webcast in second bullet point (URL embedded behind phrase "this link") of release dated April 27, 2026 has been updated. The updated release reads: CARDLYTICS ANNOUNCES TIMING OF ITS FIRST QUARTER 2026 EARNINGS RELEASE Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2026 will be released on May 7, 2026, after market close. Conference Call Details: When: May 7, 2026 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be availab

    4/27/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    SEC Filings

    View All

    Cardlytics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    6/3/26 4:26:51 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    5/20/26 4:04:14 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    5/12/26 4:10:31 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gupta Srishti A. converted options into 11,000 shares, increasing direct ownership by 179% to 17,148 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    5/21/26 4:31:59 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Francis Jonathan Edward converted options into 11,000 shares, increasing direct ownership by 72% to 26,310 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    5/21/26 4:30:24 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hill Scott A converted options into 11,000 shares, increasing direct ownership by 19% to 68,748 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    5/21/26 4:29:01 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Evans David Thomas bought $129,000 worth of shares (200,000 units at $0.65), increasing direct ownership by 170% to 317,930 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    5/19/26 4:21:59 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:46:37 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:45:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Cardlytics with a new price target

    Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

    10/11/24 8:36:58 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by Northland Capital with a new price target

    Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

    8/16/24 8:54:02 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

    8/15/24 7:18:52 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Financials

    Live finance-specific insights

    View All

    Cardlytics First Quarter 2026 Financial Results Driven By Strong Operational Performance

    Company delivers strong first quarter results: Revenues from continuing operations $34.3 million; additional $4.2 million from Bridg discontinued operations Billings from continuing operations of $58.1 million; additional $4.2 million from Bridg discontinued operations Adjusted Contribution from continuing operations of $19.7 million; additional $3.6 million from Bridg discontinued operations Successfully completed the divestiture of Bridg on March 24, 2026 Subsequently liquidated PAR shares, further bolstering the balance sheet Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the first quarter ended March 31, 2026. "The

    5/7/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    CORRECTING and REPLACING Cardlytics Announces Timing of Its First Quarter 2026 Earnings Release

    Link to webcast in second bullet point (URL embedded behind phrase "this link") of release dated April 27, 2026 has been updated. The updated release reads: CARDLYTICS ANNOUNCES TIMING OF ITS FIRST QUARTER 2026 EARNINGS RELEASE Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2026 will be released on May 7, 2026, after market close. Conference Call Details: When: May 7, 2026 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be availab

    4/27/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its First Quarter 2026 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2026 will be released on May 7, 2026, after market close. Conference Call Details: When: May 7, 2026 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that makes commerce smarter and more rewarding for everyone. We offer a range of sol

    4/27/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

    Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

    4/30/25 9:00:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    7/2/24 7:05:14 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/29/24 5:05:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/18/24 7:46:57 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology